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The role of haploidentical related allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Phila-
delphia chromosomeepositive acute lymphoblastic leukemia (Phþ ALL) is not clear. We aimed to investigate
the long-term survival of Phþ ALL patients who underwent haploidentical donor (HID)-HSCT and to analyze
the factors inﬂuencing relapse and survival after allo-HSCT. The study population included Phþ ALL patients
who underwent haploidentical related allo-HSCT. Additionally, Phþ ALL patients who underwent HLA-
matched related donor (MRD) transplants during the same period were included to compare outcomes.
BCR-ABL transcript levels were analyzed by using real-time quantitative reverse transcription PCR. Clinical
data from 139 Phþ ALL patients who received allo-HSCT in our center were analyzed. Of these patients, 101
received HID transplants and 38 received MRD transplants. At a median follow-up of 36 months, 5-year
disease-free survival (DFS) and overall survival (OS) rates in the HID transplant group were 65.8% and
74.0%, respectively. The 5-year cumulative incidence of relapse (CIR) and nonrelapse mortality (NRM) rates for
the HID transplant group were 20.3% and 15.6%, respectively. In addition, there were no differences in OS, DFS,
CIR, and NRM between the HID and MRD groups. Multivariate analysis showed that imatinib resistance was a
signiﬁcant factor inﬂuencing DFS and CIR in HID transplant patients. Haploidentical HSCT for the treatment of
Phþ ALL achieves promising long-term survival, which is comparable with that of HLA-MRD HSCT. Imatinib
resistance is a negative predictor of relapse and DFS after allo-HSCT.
 2015 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
Imatinib-incorporating induction and consolidation
chemotherapy has been reported to increase complete
remission (CR) and to improve the long-term survival of
patients with Philadelphia chromosomeepositive acute
lymphoblastic leukemia (Phþ ALL), regardless of whether
they underwent allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT) [1-4]. Although it has been reported
that imatinib mesylate in combination with intensive
chemotherapy resulted in outcomes similar to allo-HSCT in
pediatric patients with Phþ ALL [5], it has not beenedgments on page 1115.
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achieves comparable long-term survival to allo-HSCT in
adult patients. Thus, allo-HSCT is still considered the best
curative approach for adult patients with Phþ ALL [6,7].
The roles and outcomes of matched related donor (MRD)
and matched unrelated donor (MUD) allo-HSCT have been
reported [8,9]. Many studies of pretransplant imatinib
therapy and survival advantage included patients who
underwent MRD or MUD transplants [10-13]. However,
haploidentical HSCTmay be the optimal treatment choice for
patients without a MRD or MUD. Several reports from our
center demonstrated that haploidentical HSCT without
in vitro T cell depletion can achieve promising long-term
survival for patients with both malignant and nonmalig-
nant hematological diseases [14-16]. In our previous
prospective study, which investigated maintenance therapy
with imatinib post-HSCT for Phþ ALL, the donor sourceood and Marrow Transplantation.
Table 1
Patient Characteristics with Different Donor Type: Matched Related vs.
Haploidentical Transplantation
Items Matched
Related HSCT
(n ¼ 38)
Haploidentical
HSCT (n ¼ 101)
P*
Sex .692
Male 23 (60) 66 (65.3)
Female 15 (40) 35 (34.7)
Age, yr .001
<35 16 (42.1) 75 (74.2)
>35 22 (57.9) 26 (25.8)
WBC count
<30  109/L 21 (55.2) 46 (44.4) .505
>30  109/L 17 (45.8) 55 (55.6)
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[17,18]. To date, a large population study describing the
outcome of haploidentical HSCT for the treatment of Phþ ALL
and comparing the outcomes of different donor type trans-
plants between HLA-matched related and haploidentical
HSCT has not been performed.
In this study, we aimed to investigate the long-term sur-
vival of patients who underwent haploidentical HSCT for Phþ
ALL treatment and to explore risk factors associated with
relapse and long-term survival in a large cohort study. In
addition, we compared the outcomes of haploidentical HSCT
with matched related transplants for Phþ ALL during the
same period in our center.Disease status
CR1 30 (78.9) 90 (89.1) .164
>CR1 8 (21.1) 11 (10.9)
IM therapy pre-HSCT
Yes 33 (86.8) 91 (90.1) .554
No 5 (13.2) 10 (9.9)
Pre-HSCT qRT-PCR
0 15 (39.5) 46 (44.4) .569
>0 23 (60.5) 55 (55.6)
Conditioning
Bu/Cy 37 (97.3) 99 (98.0) 1.000
TBI/Cy 1 (2.7) 2 (2)
Post-HSCT qRT-PCR, 30 dMETHODS
Patient Eligibility
Allo-HSCT recipients diagnosed with Phþ ALL (age < 60 years) who
received transplants from HLA-haploidentical donors (HIDs) were eligible
for the study. In addition, HLA-MRD transplants were also included in the
study for comparison with HID transplants. The diagnosis of Phþ ALL was
based on theWorld Health Organization diagnosis criteria [19]. Patients who
displayed hypersensitivity or were determined to be imatinib resistant
before HSCT were excluded from the study. This study was reviewed and
approved by the ethics committee at Peking University People’s Hospital. All
patients provided written informed consent before transplantation.0 19 (50) 93 .000
>0 19 (50) 8
Post-HSCT IM
Yes 34 (89.5) 81 (80.2) .313
No 4 (10.5) 20 (19.8)
Start of post-HSCT IM
<3 mo 30 (88.2) 57 (70.4) .048
>3 mo 4 (11.8) 24 (29.6)
Duration of IM therapy
Post-HSCT
<3 mo 11 (32.7) 33 (40.7) .826
>3 mo 23 (67.6) 48 (60.3)
<6 mo 16 (47.1) 40 (49.4) .834
>6 mo 18 (52.9) 41 (5.6)
IM resistant
Yes 13 (34.2) 15 (14.9) .017
No 25 (65.8) 86 (85.1)
Bu indicates busulfan; TBI, total body irradiation; IM, imatinib. Values are
number of cases with percents in parentheses.Chemotherapy before Transplantation
The induction chemotherapy regimen included daunorubicin,
cyclophosphamide (Cy), vincristine, prednisone (VDCP), and L-asparaginase.
Consolidation chemotherapy regimen included hyper-CVAD (B) (metho-
trexate and cytosine arabinoside), high-dose methotrexate with/without
L-asparaginase, and the VDCP regimen, which were given in turn. After 3 to
4 courses of consolidation therapy, patients entered the HSCT program.
Prophylaxis for central nervous system leukemiawas given to every enrolled
patient, which consisted of intrathecal chemotherapy with methotrexate,
cytosine arabinoside, and dexamethasone for at least 4 doses during
induction and consolidation chemotherapy.
The enrolled patients followed the treatment diagram shown in Figure 1.
If neither an HLA-identical related donor nor an unrelated donor were
available after induction and consolidation chemotherapy (combined with
imatinib), a haploidentical family donor was an alternative. Assessments of
HLA haplotype mismatched donors were performed as described previously
[14-16].Diagnosis of 
Ph+ ALL              WHO criteria
Induction
Chemotherapy         ± Imatinib (400–600 mg/d)
Consolidation
Chemotherapy          ± Imatinib (400–600 mg/d)
HLA-matched         MUD         Haploidentical
Sibling HSCT         HSCT         Donor HSCT
Follow-up (Maintenance therapy with imatinib)
Figure 1. Treatment diagram for patients diagnosed with Phþ ALL. WHO in-
dicates World Health Organization.
* The criterion for statistical signiﬁcance was P < .05.Conditioning Regimen and Graft-versus-Host Disease Prophylaxis
Myeloablative transplant conditioning regimens were administered as
previously described [14,16-18]. For patients receiving haploidentical
transplants, the conditioning regimens were (1) total body irradiation (TBI)
with 7.7 to 12.0 Gy and Cy 1.8 g$m2d12 days; methyl-N-(2-chloroethyl)-
N-cyclohexyl-N-nitrosourea (Me-CCNU, 250 mg$kg1d1) orally once on
day 3 or (2) cytosine arabinoside (4 g$m2d1) i.v. on days 10 and 9,
busulfan (3.2 mg$kg1d1) i.v. on days 8 to 6, Cy (1.8 g$m2d1) i.v. on
days5 and4, andMe-CCNU, 250mg$kg1d1 orally once on day3. Both
conditioning regimens were supplemented with anti-human thymocyteTable 2
Engraftment and GVHD in haploidentical and matched related HSCT
Items Matched Related
HSCT (n ¼ 38)
Haploidentical
HSCT (n ¼ 101)
P*
Median ANC engraftment,
days (range)
15 (10-22) 12 (7-27) .001
Median BPC engraftment,
days (range)
15 (7-31) 14 (9-150) .657
Acute GVHD
Grades 0-I/II-IV 32/6 69/32 .045*
Chronic GVHD
0/L/E 17/15/5 36/44/20 .499
ANC indicates absolute neutrophil count; BPC, blood platelet count.
* The criterion for statistical signiﬁcance was P < .05.
Figure 2. DFS at 5 years in haploidentical and matched related HSCT (65.8% versus 61.0%, respectively; P ¼ .255).
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consecutive days (5 to 2). All transplant recipients received cyclosporine
Aebased acute graft-versus-host disease (GVHD) prophylaxis. Supportive
care was administered as described previously [14-16].
MRD Assessment
The levels of BCR-ABL transcripts in the bone marrow of patients were
determined using TaqMan-based, quantitative, real-time, reverse tran-
scription PCR (qRT-PCR) as previously described [20,21]. A complete
molecular remission was deﬁned as the negative expression of BCR-ABL by
qRT-PCR in patient bone marrow specimens. Bone marrow aspiration for
morphological and cytogenetic analysis using ﬂuorescence in situ hybridi-
zation, ﬂow cytometry, and qRT-PCR was scheduled for 1, 3, 6, 9, and 12
months post-HSCT and then once every 3 months during months 12 to 24
post-HSCT. Direct sequencing was performed to identify mutations in the
BCR-ABL kinase domain if patients had increasing levels of BCR-ABL during
imatinib therapy [22].
Imatinib Treatment after HSCT
After allo-HSCT, imatinib treatment was initiated if (1) patient
peripheral blood absolute neutrophil counts were >1.0  109/L without
granulocyte colony-stimulating factor (G-CSF) administration and theFigure 3. OS at 5 years in haploidentical and matched relatplatelet count was >50.0  109/L, regardless of BCR-ABL transcript levels, or
(2) BCR-ABL transcript levels in the bone marrow increased in 2 consecutive
tests or were high (102) after the initial engraftment. Imatinib treatment
was scheduled for 3 to 12 months after HSCT or when BCR-ABL transcript
levels were negative at least for 3 consecutive tests and complete molecular
remission was sustained for at least 3 months, as described in our previous
report [17,18]. Additional criteria for initiation of treatment included
whether patients could tolerate oral imatinib therapy without developing
gut GVHD or a life-threatening infection. The initial dose of imatinibwas 400
mg/d for adults (age> 17 years) and 260 mg$m2$d1 for children (age< 17
years). The daily dose of imatinib was adjusted according to the National
Comprehensive Cancer Network practice guidelines regarding the
management of imatinib toxicity (version 2005) [23].Deﬁnitions
Imatinib-resistance was deﬁned as (1) an increase in BCR-ABL transcript
levels in 2 consecutive tests separated by1 month or (2) detection of point
mutations in the BCR-ABL kinase domain during imatinib therapy or during
readministration of imatinib post-transplant. Relapse was deﬁned as >5%
bone marrow blasts, the detection of circulating blasts, or the development
of extramedullary leukemia.ed HSCT (74.0% versus 68.2%, respectively; P ¼ .457).
Table 3
Univariate Analysis of Signiﬁcant Predictors of DFS, OS, and CIR in Hap-
loidentical Transplants
Risk Factors OS DFS CIR
Gender
Male, n ¼ 66 75.6% 65.9% 20.2%
Female, n ¼ 35 71.9% 65.5% 21.0%
P .628 .981 .863
Age
<35 yr (n ¼ 75) 71.2% 63.6% 22.3%
35 yr (n ¼ 26) 84.1% 71.4% 16.7%
P .396 .360 .435
WBC count
<30  109/L (n ¼ 59) 83.3% 71.2% 21.3%
30  109/L (n ¼ 42) 71.0% 63.0% 17.1%
P .333 .449 .926
Disease status at HSCT
CR1 (n ¼ 90) 76.7% 67.8% 19.0%
>CR1 (n ¼ 11) 58.2% 51.9% 30.7%
P .337 .350 .926
IM pre-HSCT
Yes (n ¼ 91) 73.7% 66.1% 20.1%
No (n ¼ 10) 70.0% 60.0% 22.9%
P .716 .618 .722
qRT-PCR BCR-ABL pre-HSCT
>0 (n ¼ 46) 87.2% 74.0% 17.8%
<0 (n ¼ 55) 62.4% 59.9% 22.6%
P .007 .031 .455
Conditioning
TBI/Cy (n ¼ 2) 50.0% 50.0% 50.0%
Bu/Cy (n ¼ 99) 75.1% 66.4% 19.4%
P .410 .650 .277
qRT-PCR BCR-ABL post-HSCT
(þ30 d) >0 (n ¼ 93) 76.4% 66.2% 19.5%
<0 (n ¼ 8) 56.2% 60.0% 30.0%
P .320 .584 .425
IM post-HSCT
Yes ¼ 81 81.5% 72.2% 17.3%
No ¼ 20 44.4% 39.4% 20.6%
P .000 .000 .681
Start of IM post-HSCT
<3 mo (n ¼ 57) 84.1% 76.8% 81.8%
>3 mo (n ¼ 24) 81.0% 64.6% 76.8%
P .854 .481 .654
Duration of IM
<3 mo (n ¼ 32) 76.0% 73.7% 83.6%
>3 mo (n ¼ 49) 87.7% 69.3% 76.7%
P .201 .846 .727
<6 mo (n ¼ 40) 77.5% 69.3% 76.4%
>6 mo (n ¼ 41) 88.3% 74.2% 83.1%
P .215 .418 .502
Acute GVHD
Grades 0-I (n ¼ 69) 76.9% 68.0% 26.5%
Grades II-IV (n ¼ 32) 61.4% 55.5% 14.4%
P .023 .123 .227
Chronic GVHD
0 (n ¼ 36) 77.3% 56.7% 26.6%
L (n ¼ 44) 73.3% 70.8% 17.9%
E (n ¼ 20) 74.3% 58.9% 17.0%
P .989 .718 .658
IM resistant
Yes (n ¼ 15) 59.3% 12.5% 81.2%
No (n ¼ 86) 76.7% 74.0% 10.1%
P .337 .002 .000
The criterion for statistical signiﬁcance was P < .05.
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Parametric tests were performed using chi-square or Fisher’s exact tests.
The Mann-Whitney U test was used for nonparametric tests. Univariate
analysis of disease-free survival (DFS), overall survival (OS), and cumulative
incidence of relapse (CIR) for enrolled patients was conducted using Kaplan-
Meier analysis and the log-rank test. Multiple regression analysis for DFS,
OS, and CIR was conducted using a multiple Cox regression model. The
covariates that were adjusted in the multiple regression models included
factors identiﬁed in the univariate analysis with P< .1. Kaplan-Meier analysis
was used to estimate DFS and OS, whereas the cumulative incidence wascalculated for nonrelapse mortality (NRM), GVHD, and relapse rate. The
relapse rate and incidence of GVHD were also calculated by accounting for
the competing risk of death due to other complications using a Fine-Gray
model. Data analysis was performed using the SPSS 16.0 (IBM, Armonk,
NY) and R (Bell Labs, New Providence, NJ) software packages, and P < .05
was considered statistically signiﬁcant.
RESULTS
Enrollment
From May 2005 to September 2012, 145 consecutive
patients received allo-HSCT and 120 patients received
imatinib maintenance therapy post-transplant. Among these
patients, 101 received HID transplants, 38 received MRD
transplants, and 6 received MUD transplants. Clinical data of
139 Phþ ALL patients who received either HID or MRD
transplantation were analyzed. The median age of patients
who received haploidentical transplants was 25 years (range,
3 to 51 years), and the median age of patients who received
MRD transplants was 39 years (range, 7 to 62 years). The
demographic characteristics and relevant transplantation
data of patients undergoing HID transplants and MRD HSCT
are shown in Table 1.
Imatinib Treatment
All enrolled patients achieved hematological remission
and were in complete cytogenetic remission after initial
engraftment. Additionally, 120 patients received imatinib
therapy at a median time of 72 days post-HSCT (range, 20 to
270), and the median duration of imatinib therapy was 180
days (range, 30 to 540). In the haploidentical HSCT group, 81
patients received imatinib therapy at a median time of 78
days post-HSCT (range, 20 to 270), and the median duration
of imatinib therapy was 180 days (range, 30 to 540). Twenty-
ﬁve patients did not undergo imatinib therapy because of
pancytopenia (n ¼ 3), severe infections (n ¼ 8), severe gut
GVHD (n ¼ 8), or personal decisions (n ¼ 6).
Engraftment and GVHD
All 101 haploidentical transplant patients achieved
myeloid engraftment, and all patients except 1 achieved
platelet engraftment after HSCT (Table 2). All 101 patients
survived >28 days and were evaluated for the development
of acute GVHD. The number of patients who developed acute
and chronic GVHD is shown in Table 2. In the HID group at
100 days post-HSCT, the cumulative incidence of grades I to
IV, II to IV, and III to IV acute GVHDwas 68.3% 4.6%, 38.4%
5.7%, and 17.6%  5.2%, respectively. One hundred patients
survived >100 days post-transplant and were evaluated for
chronic GVHD. The cumulative incidence of chronic and
extensive chronic GVHD after 5 years for haploidentical HSCT
was 68.5% .3% and 19.5% 7.1%, respectively. The incidence
of grades III to IV acute and chronic GVHD did not differ
between the HID group and MRD group (17.8% versus 8.2%,
P ¼ .343; and 68.5% versus 56.8%, P ¼ .620, respectively).
However, the incidence of grades II to IV acute GVHD was
higher in the HID group than in the MRD group (38.4.1% 
5.3% versus 16.2%  6.1%, P ¼ .005, respectively).
NRM and Relapse Rates
At the time of the last follow-up (December 31, 2013), 16
patients in the haploidentical group had a relapse. Relapse
included hematological relapse (n ¼ 13) and extramedullary
leukemia relapse (n ¼ 3) at a median time of 14 months
(range, 2 to 36). No cytogenetic relapse occurred without
concurrent hematological relapse. There was no difference in
the 5-year CIR between the HID and MRD transplant groups
Table 4
Multivariate Analysis of Signiﬁcant Predictors for DFS, OS, and CIR in Haploidentical Transplants
Variable DFS OS CIR
HR 95% CI P* HR 95% CI P* HR 95% CI P*
BCR-ABL(þ)pre-HSCT .6 .2-1.3 .236 .2 .1-1.1 .100 .4 .1-1.5 .277
IM therapy post-HSCT .2 .1-.5 .001 .2 .1-.6 .004 .7 .2-2.1 .556
IM resistance 3.2 1.5-7.0 .002 1.6 .6-4.4 .333 8.9 3.2-24.4 .000
95% CI indicates 95% conﬁdence interval.
* The criterion for statistical signiﬁcance was P < .05.
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There was also no difference in the NRM between the HID
and MRD groups (15.6%  4.0% versus 9.6%  5.3%, respec-
tively, P ¼ .751).
OS and DFS
At a median follow-up of 36 months (range, 2.5 to 104),
the estimated 5-year probabilities of DFS and OS were 65.8%
 5.2% and 74.0%  5.0% (P ¼ .255), respectively, for the HID
group and 61.0%  8.2% and 68.2%  9.0%, respectively, for
the MRD group (P ¼ .457) (Figures 2 and 3). Twenty-three
patients died after HSCT. The causes of death included
relapse (n ¼ 9), GVHD (n ¼ 3), infection (n ¼ 7), and other
(n ¼ 4).
Factors Affecting Long-Term Survival and Relapse Rate
For 101 haploidentical HSCT patients, univariate analysis
revealed that the pre-HSCT BCR-ABL transcript level (detec-
ted by qRT-PCR) was a signiﬁcant factor affecting DFS and OS
(P ¼ .007 and .031, respectively). Imatinib resistance was a
signiﬁcant factor that inﬂuenced DFS and CIR (P ¼ .002 and
.000, respectively) (Table 3). Based on amultivariate analysis,
imatinib resistance was a signiﬁcant factor for DFS and CIR in
HID HSCT. Imatinib therapy after transplant was a signiﬁcant
factor for DFS and OS in HID transplantation (Table 4).
Multivariate analysis of 38 MRD transplant patients revealed
that imatinib therapy post-HSCT was a signiﬁcant factor for
CIR, DFS, and OS (Table 5).
Relapse and Imatinib Resistance
During the post-transplant follow-up period, 28 patients
in both the HID andMRD transplant groupswere determined
to be imatinib resistant. Fifteen of these patients were in the
HID group. Imatinib resistance occurred during either ima-
tinib therapy or imatinib readministration after disease
recurrence. Kinase domain mutations in BCR-ABL were
detected in 15 of 28 patients. Among these patients, the
T315I mutation was detected in 11 patients, and other point
mutations in BCR-ABL were detected in 4 patients. Twenty-
four of these patients were switched to treatment with
second-generation tyrosine kinase inhibitors, including
dasatinib (n ¼ 21) and nilotinib (n ¼ 3), and received
chemotherapy plus donor lymphocyte infusion. Of these
patients, 8 did not progress to hematological relapse. SixteenTable 5
Multivariate Analysis of Signiﬁcant Predictors of DFS, OS, and CIR in HLA-Matched
Variable DFS OS
HR 95% CI P* HR
Status (CR1/>CR1) .3 .1-1.1 .081 .2
IM therapy post-HSCT 13 3.7-49 .001 .1
IM resistance 6.0 2.3-16 .002 3.1
* The criterion for statistical signiﬁcance was P < .05.patients eventually experienced clinical relapse, and 10 of
them died because of it. Only 4 patients received chemo-
therapy plus donor lymphocyte infusion or a second HSCT,
and all died (3 of 4 patients died of relapse). During the
median follow-up period of 27.7 months, the estimated
3-year DFS and OS rates for 28 imatinib-resistant patients
were 14.8% and 52.3%, respectively. The 3-year DFS and
OS rates were 12.5% and 59.3%, respectively, in 15 imatinib-
resistant patients in the HID group.
DISCUSSION
In recent years, imatinib combined with intensive
chemotherapy before HSCT has greatly improved DFS and OS
in patients with Phþ ALL compared with control subjects
[1,3,10-13]. In these studies, transplantation included both
HLA-MRDs and MUDs. However, relapse is still one of the
most common treatment failures during long-term follow-
up. Therefore, it is necessary to investigate other treatment
modalities, including alternative donor transplants (ie,
mismatched related transplants) or other conditioning regi-
mens for the treatment of Phþ ALL. In our study, 101 patients
received haploidentical HSCT, with 5-year DFS and OS rates
reaching 65.8% and 74.0%, respectively. This is the largest
published report to date on patients with Phþ ALL who
received haploidentical HSCT. The patients who underwent
haploidentical transplant achieved identical outcomes
compared with matched related transplants in our center
during the same period and matched sibling transplants
reported by other centers, although the demographic char-
acteristics of the patients were not completely comparable
between the different donor type groups and the different
centers. There was also no difference in the NRM between
the 2 transplant groups.
Most Phþ ALL patients treated with allo-HSCT receive TBI/
Cy as the conditioning regimen. Laport et al. [24] reported that
fractionated TBI and high-dose VP16, with or without Cy,
confers long-term survival in Ph ALL patients. In their study,
the relapse rate did not signiﬁcantly differ between patients in
ﬁrst CR (CR1) and beyond CR1 at transplant. In our study, all
patients except 3 received modiﬁed busulfan/Cy-based con-
ditioning and a novel approach using G-CSFeprimed bone
marrow plus G-CSFemobilized peripheral blood stem cells
without in vitro T cell depletion after conditioning in the HID
group [14,16-18].We achieved an outcome consistentwith theRelated Transplants
CIR
95% CI P* HR 95% CI P*
.06-.6 .018 .4 .1-1.5 .287
.02-.4 .001 22 4.3-112 .002
.8-9.4 .092 16 3.8-67 .001
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Phþ ALL in the era of imatinib. Factors affecting relapse in Phþ
ALL patients after transplant have been discussed in many
reports; they include remission status at transplant and
minimal residual disease pre- and post-transplant [25,26].
Before the development of imatinib, Stirewalt et al. [25]
reported that the BCR-ABL transcript level post-transplant
was a signiﬁcant predictor of clinical relapse (P ¼ .001).
Many studies indicated that OS and progression-free survival
were signiﬁcantly better for patients with Phþ ALL who
received transplants in CR1 than in patients with advanced
disease who received HSCT [9,27]. In our study, detection of
BCR-ABL transcript levels post-transplant (þ30 days) and
disease status (>CR1) were not signiﬁcant factors for pre-
dicting clinical relapse in HID transplant patients. We believe
this can be partially explained by the effects of imatinib
maintenance therapy after HSCT. Kebriaei et al. [26]
demonstrated that the cumulative incidence of grades II to
IV acute GVHD was associated with a signiﬁcantly better
progression-free survival in multivariate analyses (P ¼ .01)
for Phþ ALL after allo-HSCT. Additionally, Yanada et al. [28]
demonstrated that chronic GVHD was associated with a
lower risk of relapse without an increase in the risk of
treatment-related mortality and that Phþ ALL patients had
better survival (P ¼ .0217). In our study, the incidence of
grades II to IV acute GVHD was higher in the HID group than
in the MRD group (P ¼ .03). The incidence of chronic GVHD
was as high as 68.5%. A recent study performed in our center
to evaluate haploidentical transplant for the treatment of
Ph ALL showed no differences in DFS and OS between
standard-risk and high-risk ALL patients [29]. We also found
superior graft-versus-leukemia (GVL) effects associated with
HID transplants compared with MRD transplants for high-
risk acute leukemia [30]. Therefore, we hypothesize that
the favorable leukemia-free survival of haploidentical HSCT
patients beyond CR1 and of patients detected with the BCR-
ABL transcript post-transplant might primarily be due to the
GVL effect caused by the high HLA disparity.
Our data also showed for grades III to IV acute GVHD no
difference between the 2 donor type groups, and the NRM in
haploidentical transplants was 15.6%, which was not
different from that of MRD transplants. These results are
consistent with the beneﬁcial effect of mild to moderate
GVHD, which was associated with a lower relapse rate but
not an increased NRM [31-33]. Our previous study showed
that maintenance therapy with imatinib post-HSCT reduced
the relapse rate [18]. The donor types in this study included
MRD (n ¼ 19) and HID related (n ¼ 60) and unrelated donors
(n ¼ 3). Here, we found that imatinib therapy post-HSCT is
not a signiﬁcant factor affecting relapse rate in the HID
transplant group, but it was still a signiﬁcant inﬂuencing
relapse in the MRD transplant group. We believe this is
because of the small number of patients in the HID group
who did not receive imatinib post-HSCT and because of the
potential GVL effect conferred by HID transplant, which may
inﬂuence the relapse rate in a multivariate analysis. In the
future, a carefully designed controlled study may better
deﬁne this problem.
Other studies showed that age was also a predictor for
worse OS and DFS [26]. Our study classiﬁed patients as
younger or older than 35 years, and more patients younger
than 35 years were in HID group. Therefore, the median age
was younger in the HID group. This is a limitation of the
present study. With more older patients receiving HID
transplants, we can better demonstrate our study conclusion.Imatinib resistance remains a problem in a substantial
proportion of patients with Phþ ALL during the period of
imatinib therapy, and it is frequently observed with disease
recurrence. Second-generation tyrosine kinase inhibitors (ie,
dasatinib and nilotinib) have demonstrated promising efﬁ-
cacy in the treatment of imatinib-resistant Phþ ALL [34,35].
However, the prognosis of patients who showed relapse after
allo-HSCT is extremely poor. We described imatinib resis-
tance as a negative predictor for relapse and DFS after HSCT.
Although our study showed that second-generation imatinib
combined with donor lymphocyte infusion might improve
the OS of imatinib-resistant patients after HSCT, the long-
term survival is dismal with longer follow-up. Therefore,
additional studies are required to investigate new treatment
modalities and further reduce the relapse rate of Phþ ALL
patients after allo-HSCT. In our present study we showed
that less patients developed imatinib resistance in the HID
group after transplant, which should be another limitation of
the study. We believe this may be associated with more
intensive GVL effect provided by HID transplants to reduce
the MRD level, which could potentially develop imatinib
resistance after transplant.
We conclude that haploidentical HSCT for Phþ ALL
achieves promising long-term survival compared with
matched related transplants, without increasing NRM, which
suggests that haploidentical HSCT is an alternative approach
for Phþ ALL patients without HLA matched donors. Imatinib
resistance is a signiﬁcant factor that affects relapse and DFS
after transplantation.ACKNOWLEDGMENTS
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